CHEK2 Antikörper (N-Term)
-
- Target Alle CHEK2 Antikörper anzeigen
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
-
Bindungsspezifität
- N-Term
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser CHEK2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC)
- Sequenz
- MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS
- Homologie
- Human: 100%
- Produktmerkmale
- This is a rabbit polyclonal antibody against CHEK2. It was validated on Western Blot using a cell lysate as a positive control.
- Aufreinigung
- Affinity Purified
- Immunogen
- The immunogen is a synthetic peptide directed towards the N terminal region of human CHEK2
- Top Product
- Discover our top product CHEK2 Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilutions should be determined experimentally by the investigator.
- Kommentare
-
Antigen size: 514 AA
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
Parkinsonism and midbrain dysfunction after shunt placement for obstructive hydrocephalus." in: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, Vol. 13, Issue 3, pp. 373-8, (2006) (PubMed).
: "
-
Parkinsonism and midbrain dysfunction after shunt placement for obstructive hydrocephalus." in: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, Vol. 13, Issue 3, pp. 373-8, (2006) (PubMed).
-
- Target
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
- Andere Bezeichnung
- CHEK2 (CHEK2 Produkte)
- Synonyme
- CDS1 antikoerper, CHK2 antikoerper, HuCds1 antikoerper, LFS2 antikoerper, PP1425 antikoerper, RAD53 antikoerper, hCds1 antikoerper, fa66f08 antikoerper, wu:fa66f08 antikoerper, zgc:55865 antikoerper, Cds1 antikoerper, HUCDS1 antikoerper, Rad53 antikoerper, Chk2 antikoerper, cds1 antikoerper, chek2 antikoerper, chk2 antikoerper, hucds1 antikoerper, lfs2 antikoerper, pp1425 antikoerper, rad53 antikoerper, checkpoint kinase 2 antikoerper, serine/threonine-protein kinase chk2 antikoerper, checkpoint kinase 2 L homeolog antikoerper, CHEK2 antikoerper, chek2 antikoerper, Chek2 antikoerper, MCYG_07308 antikoerper, chek2.L antikoerper
- Hintergrund
-
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. CHEK2 is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, CHEK2 is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in its gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in its gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases.In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
Alias Symbols: RP11-436C9.1, CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53, hCds1
Protein Interaction Partner: SRPK1, PPP2CA, PLK1, CHEK2, PRKDC, ATM, POLR2L, RCHY1, VHL, UBC, NR4A1, ELAVL1, CDC25A, ARHGAP1, PER3, CDC25C, CUL1, CUL4A, KPNA2, APP, STRAP, TP53, BRCA1, RB1, DAPK3, UBR5, PML, MDM2, BRCA2, KAT2B, LATS2, PSME3, TRIM28, RNF8, STAT1, PPP2R5E, PPP2R5D, PPP
Protein Size: 514 - Molekulargewicht
- 58 kDa
- Gen-ID
- 11200
- NCBI Accession
- NM_145862, NP_665861
- Pathways
- p53 Signalweg, Apoptose, Zellzyklus
-